Title: President and Professor

Prof. Xu administrates the Executive Office and the Clinical Trials Center and Cancer Communications.

Department: Medical Oncology

Description:

President and professor of Sun Yat-sen University Cancer Center, Director of State Key Laboratory of Oncology in South China, Member of the Academic Committee of the Chinese Academy of Medical Sciences, Chairman of the Chinese Society of Clinical Oncology (CSCO), Vice-chairman of China Anti-cancer Association (CACA) and Editor in Chief of Cancer Communications.

Professor Xu has made profound contributions in the research and treatment of intestinal cancer, advancingboth theory and practice in the field. His pioneering work has elevated China's intestinal cancer early diagnosis and precision treatment to an internationally advanced level. His groundbreaking contributions have redefined the immunotherapy strategy for GI cancer, driving global progress in this specialized domain. His clinical research on Treprizumab, a domestically developed innovative PD-1 antibody, garnered FDA approval in the United States on October 28, 2023. This marks a historic milestone, as it's the first time Chinese original biological monoclonal antibodies have obtained US market approval.

He has published more than 200 peer-reviewed papers in top international journals such as JAMA, Cancer Cell, Nature Medicine, Nature Materials and Lancet Oncology. His standing as a "Highly Cited Researcher" by Clarivate Analytics underscores his influence and recognition within the scientific community. He was awarded two Second Prizes of the State Scientific and Technological Progress Award, and the National Innovation Competition Award.